July 2026 Catalyst Events
- 2026-07-01: Revascor (Rexlemestrocel-L) - (DREAM-HF) — Mesoblast Limited — Submission
- 2026-07-01: INT230-6 - (INVINCIBLE-4) — Intensity Therapeutics Inc. — Phase 2
- 2026-07-01: Namodenoson - (CF102-222PC) — Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) — Phase 2a
- 2026-07-01: CRENESSITY (Crinecerfont) — Neurocrine Biosciences Inc. — Phase 2
- 2026-07-01: ARAKODA regimen (tafenoquine) - (open label) - (B-FREE) — 60 Degrees Pharmaceuticals Inc. — Phase 2
- 2026-07-01: NCEL-101 + tegoprubart (AT-1501) — NewcelX Ltd. — End of Phase Meeting
- 2026-07-01: CASGEVY (exagamglogene autotemcel [exa-cel] — CRISPR Therapeutics AG — Submission
- 2026-07-01: ART26.12 — Artelo Biosciences Inc. — Conference Presentation
- 2026-07-01: fanregratinib - (HMPL-453) — HUTCHMED (China) Limited — Conference Presentation
- 2026-07-02: Divarasib - (Krascendo 1) — Roche Holding AG ADR — Conference Presentation
- 2026-07-02: Zoldonrasib (RMC-9805) — Revolution Medicines Inc - Ordinary Shares — Conference Presentation
- 2026-07-02: [212Pb] Pb-MP0712 — Molecular Partners AG — Initial Data
- 2026-07-02: Daraxonrasib (RMC-GI-102) plus gemcitabine and nab-paclitaxel - (RASolute 303) — Revolution Medicines Inc - Ordinary Shares — Conference Presentation
- 2026-07-02: botensilimab (BOT) and balstilimab (BAL) - (BBoPCO) — Agenus Inc. — Conference Presentation
- 2026-07-02: Zoldonrasib (RMC-9805) — Revolution Medicines Inc - Ordinary Shares — Conference Presentation
- 2026-07-03: Daraxonrasib - (RASolute 304) — Revolution Medicines Inc - Ordinary Shares — Conference Presentation
- 2026-07-03: Daraxonrasib (RMC-GI-102) plus gemcitabine and nab-paclitaxel - (RASolute 303) — Revolution Medicines Inc - Ordinary Shares — Conference Presentation
- 2026-07-06: VXA-CoV2-1 - (XBB) — Vaxart Inc. — Topline Data
- 2026-07-06: Piclidenoson - (COMFORT) — Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) — Interim Data
- 2026-07-06: OST-HER2 (AOST-2121) — OS Therapies Incorporated — Submission
- 2026-07-06: Emavusertib (CA-4948) and pembrolizumab — Curis Inc. — Initial Data
- 2026-07-06: deucrictibant IR (PHVS416) - (RAPIDe-3) — Pharvaris N.V. — Regulatory Decision
- 2026-07-06: Botensilimab plus balstilimab - (C-800-01) — Agenus Inc. — Phase 1b
- 2026-07-06: LUPKYNIS (Voclosporin) in combination with belimumab, obinutuzumab or anifrolumab - (PRESERVE) — Aurinia Pharmaceuticals Inc — Phase 3
- 2026-07-06: IMM-529 — Immuron Limited — Phase 2
- 2026-07-06: BRIUMVI (ublituximab-xiiy) 150 mg/6 mL Injection for IV — TG Therapeutics Inc. — Phase 2
- 2026-07-06: BEAM-304 — Beam Therapeutics Inc. — Conference Presentation
- 2026-07-07: VCA-894A — Vanda Pharmaceuticals Inc. — Phase 1
- 2026-07-07: ATH434-201 — Alterity Therapeutics Limited — End of Phase Meeting
- 2026-07-07: Mitapivat (AG-348) - (RISE UP) — Agios Pharmaceuticals Inc. — Regulatory Decision
- 2026-07-07: TRUTAKNA (atacicept-vymj) - (ORIGIN 3) — Vera Therapeutics Inc. — Interim Data
- 2026-07-07: Sunosi (Solriamfetol) - (FOCUS-3) — Axsome Therapeutics Inc. — Phase 3
- 2026-07-07: TEV-’408 — Teva Pharmaceutical Industries Limited American Depositary Shares — Phase 1b
- 2026-07-07: TTI-109 — Tvardi Therapeutics Inc. — Phase 1
- 2026-07-07: ONP-002 - (Australian trial) — Oragenics Inc. — Submission
- 2026-07-07: Buntanetap (ANVS401) — Annovis Bio Inc. — Submission
- 2026-07-07: COMP360 psilocybin - (COMP006) — COMPASS Pathways Plc — Submission
- 2026-07-07: Atacicept - (ORIGIN 3) — Vera Therapeutics Inc. — Regulatory Decision
- 2026-07-08: IMCIVREE (setmelanotide) — Rhythm Pharmaceuticals Inc. — Submission
- 2026-07-08: Urcosimod (OK-101) - (NEPTUNE) — OKYO Pharma Limited — End of Phase Meeting
- 2026-07-08: SAT-3247 (LT-001) - (TRAILHEAD) — Satellos Bioscience Inc. — Interim Data
- 2026-07-08: ZORYVE (roflumilast) Cream 0.05% - (INTEGUMENT-INFANT) — Arcutis Biotherapeutics Inc. — Regulatory Decision
- 2026-07-08: UGN-501 — UroGen Pharma Ltd. — IND-Enabling
- 2026-07-08: SER-155 — Seres Therapeutics Inc. — Phase 2
- 2026-07-08: varegacestat (AL102) - (RINGSIDE) — Immunome Inc. — Regulatory Decision
- 2026-07-08: Ateganosine (THIO-101) — MAIA Biotechnology Inc. — Interim Data
- 2026-07-08: SER-155 — Seres Therapeutics Inc. — Conference Presentation
- 2026-07-08: SAT-3247 (LT-001) - (TRAILHEAD) — Satellos Bioscience Inc. — Conference Presentation
- 2026-07-08: SAT-3247 (CL-101) - (BASECAMP) — Satellos Bioscience Inc. — Conference Presentation
- 2026-07-09: FT819-102 — Fate Therapeutics Inc. — Conference Presentation
- 2026-07-09: SER-252 (POZ-apomorphine) in combination with enFuse — Serina Therapeutics Inc. — Initial Data
- 2026-07-09: Dysport (abobotulinumtoxinA) - (C-BEOND) — Ipsen ADR — Topline Data
- 2026-07-09: Dysport (abobotulinumtoxinA) - (E-BEOND) — Ipsen ADR — Topline Data
- 2026-07-09: QRX003 — Quoin Pharmaceuticals Ltd. — Submission
- 2026-07-09: DA-1726 — MetaVia Inc. — Topline Data
- 2026-07-09: FB102 — Forte Biosciences Inc. — Phase 1b
- 2026-07-09: FT839 — Fate Therapeutics Inc. — Conference Presentation
- 2026-07-09: HEPZATO — Delcath Systems Inc. — Conference Presentation
- 2026-07-09: Wainua (eplontersen) - (CARDIO-TTRansform) — AstraZeneca PLC — Conference Presentation
- 2026-07-09: XPRO1595 - (MINDFuL) — INmune Bio Inc. — Submission
- 2026-07-09: DCVax-L — Northwest Biotherapeutics Inc — End of Phase Meeting
- 2026-07-09: FT819-102 — Fate Therapeutics Inc. — Conference Presentation
- 2026-07-10: Zelebrudomide (NX-2127) — Nurix Therapeutics Inc. — Submission
- 2026-07-10: MIRA-55 — MIRA Pharmaceuticals Inc. — Preclinical
- 2026-07-10: BL1107 (WB007) — Bausch + Lomb Corporation — Topline Data
- 2026-07-10: DNL628 (OTV:MAPT) — Denali Therapeutics Inc. — Preclinical
- 2026-07-10: DNL921 (ATV:Abeta) — Denali Therapeutics Inc. — Preclinical
- 2026-07-10: NX-1607 — Nurix Therapeutics Inc. — Submission
- 2026-07-10: PADCEV (enfortumab vedotin-ejfv) plus KEYTRUDA (pembrolizumab) - (KEYNOTE-B15/EV-304) — Astellas Pharma Inc. ADR — Conference Presentation
- 2026-07-11: Sutacimig — Hemab Therapeutics Holdings Inc. — Conference Presentation
- 2026-07-12: EVX-V1 — Evaxion A/S — Conference Presentation
- 2026-07-12: CAD-1005 (formerly VLX-1005) — Cadrenal Therapeutics Inc. — Conference Presentation
- 2026-07-12: Diranersen (IONIS-MAPTRx/BIIB080) - (CELIA) — Biogen Inc. — Conference Presentation
- 2026-07-13: ERAS-0015 — Erasca Inc. — Phase 1
- 2026-07-13: VOXZOGO (Vosoritide) — BioMarin Pharmaceutical Inc. — Regulatory Decision
- 2026-07-13: LEQEMBI IQLIK (lecanemab-irmb)(at-home injection) — Biogen Inc. — Approved
- 2026-07-13: Eftilagimod alpha + chemo+ anti-PD-1 - (INSIGHT-003) — Immutep Limited — Interim Data
- 2026-07-13: VOXZOGO (Vosoritide) — BioMarin Pharmaceutical Inc. — Regulatory Decision
- 2026-07-13: Pevifoscorvir (ALG-000184) - (B-SUPREME) — Aligos Therapeutics Inc. — Topline Data
- 2026-07-13: CAD-1005 (formerly VLX-1005) — Cadrenal Therapeutics Inc. — Phase 2
- 2026-07-13: mezigdomide (CELMoD (CC-92480)) in combination with carfilzomib and dexamethasone (MeziKd) - (SUCCESSOR-2) — Bristol-Myers Squibb Company — Regulatory Decision
- 2026-07-13: Allocetra - (ENX-CL-05-001) — Enlivex Ltd. — End of Phase Meeting
- 2026-07-13: Eftilagimod alpha (efti) - (TACTI-004/KEYNOTE-F91) — Immutep Limited — Interim Data
- 2026-07-13: Bempikibart - (SIGNAL-AA) — Q32 Bio Inc. — End of Phase Meeting
- 2026-07-13: ION337 - (ASCEND) — Ionis Pharmaceuticals Inc. — Phase 1
- 2026-07-13: VGA039 (latarcibart) - (VIVID-6) — Incyte Corporation — Phase 1/2
- 2026-07-13: ART27.13 - (CAReS) — Artelo Biosciences Inc. — Conference Presentation
- 2026-07-13: AP-SA02 - (diSARM) — Armata Pharmaceuticals Inc. — Submission
- 2026-07-13: Laromestrocel (lomecel-B) - (CLEAR MIND) — Longeveron Inc. — Phase 2a
- 2026-07-13: VY1706 — Voyager Therapeutics Inc. — Preclinical
- 2026-07-13: EVX-V1 — Evaxion A/S — Preclinical
- 2026-07-13: HMB-002 - (VELORA Discover) — Hemab Therapeutics Holdings Inc. — Initial Data
- 2026-07-13: Bempikibart - (SIGNAL-AA) — Q32 Bio Inc. — Topline Data
- 2026-07-13: Kisunla (donanemab) - (TRAILBLAZER-ALZ 2) — Eli Lilly and Company — Conference Presentation
- 2026-07-13: VY1706 — Voyager Therapeutics Inc. — Conference Presentation
- 2026-07-13: Laromestrocel (lomecel-B) - (CLEAR MIND) — Longeveron Inc. — Conference Presentation
- 2026-07-14: Rinzimetostat (ORIC-944) - (Himalayas-1) — Oric Pharmaceuticals Inc. — Phase 3
- 2026-07-14: REVTORPYK Gedatolisib - (VIKTORIA-1) — Celcuity Inc. — Conference Presentation
- 2026-07-14: Sutacimig — Hemab Therapeutics Holdings Inc. — Phase 2
- 2026-07-14: CardiolRx - (MAvERIC) — Cardiol Therapeutics Inc. — Conference Presentation
- 2026-07-14: Diranersen (IONIS-MAPTRx/BIIB080) - (CELIA) — Ionis Pharmaceuticals Inc. — Phase 2
- 2026-07-14: ATR 1072 — Atrium Therapeutics Inc. — Initial Data
- 2026-07-14: Neflamapimod - (RewinD-LB) — CervoMed Inc. — Interim Data
- 2026-07-14: ACU193 - (ALTITUDE-AD) — Acumen Pharmaceuticals Inc. — Interim Data
- 2026-07-14: Neflamapimod - (RewinD-LB) — CervoMed Inc. — Conference Presentation
- 2026-07-14: Obicetrapib - (BROADWAY) — NewAmsterdam Pharma Company N.V. — Conference Presentation
- 2026-07-14: Diranersen (IONIS-MAPTRx/BIIB080) - (CELIA) — Biogen Inc. — Conference Presentation
- 2026-07-14: HMB-002 - (VELORA Discover) — Hemab Therapeutics Holdings Inc. — Conference Presentation
- 2026-07-15: VDPHL01 - (207) — Veradermics Incorporated — Topline Data
- 2026-07-15: INT230-6 - (INVINCIBLE-4) — Intensity Therapeutics Inc. — Phase 2
- 2026-07-15: ALLO-316 - (TRAVERSE) — Allogene Therapeutics Inc. — Phase 1
- 2026-07-15: ACU193 - (ALTITUDE-AD) — Acumen Pharmaceuticals Inc. — Conference Presentation
- 2026-07-15: ERNA-101 — Ernexa Therapeutics Inc. — Submission
- 2026-07-15: Reboxetine (AXS-12) - (ENCORE) — Axsome Therapeutics Inc. — Regulatory Decision
- 2026-07-15: SCI-110 — SciSparc Ltd. — Phase 2b
- 2026-07-15: NEO212 — NeOnc Technologies Holdings Inc. — End of Phase Meeting
- 2026-07-15: ATR-COSF — Azitra Inc — Topline Data
- 2026-07-15: ACU401 — Acumen Pharmaceuticals Inc. — Topline Data
- 2026-07-15: ENV-105 (carotuximab) in combination with osimertinib (Tagrisso) — Kairos Pharma Ltd. — Interim Data
- 2026-07-15: RT-114 — Rani Therapeutics Holdings Inc. — Initial Data
- 2026-07-15: MN-166 (ibudilast) - (SEANOBI)(NIH EAP) — MediciNova Inc. — Phase 1
- 2026-07-15: Gazyva (obinutuzumab) - (MAJESTY) — Roche Holding AG ADR — Phase 3
- 2026-07-17: Gedatolisib with Fulvestrant - (VIKTORIA-1) — Celcuity Inc. — Regulatory Decision
- 2026-07-18: ANX007 - (ARCHER-II) — Annexon Inc. — Conference Presentation
- 2026-07-18: Tinlarebant (LBS-008) - (DRAGON) — Belite Bio Inc — Conference Presentation
- 2026-07-18: 4D-150 - (PRISM) — 4D Molecular Therapeutics Inc. — Conference Presentation
- 2026-07-26: FUROSCIX ReadyFlow Autoinjector (SCP-111) — MannKind Corporation — Regulatory Decision
- 2026-07-29: Deramiocel (CAP-1002) - (HOPE-2) — Capricor Therapeutics Inc. — Regulatory Decision
- 2026-07-29: LYTENAVA (bevacizumab-vikg) / ONS-5010 - (NORSE EIGHT) — Outlook Therapeutics Inc. — Regulatory Decision
- 2026-07-29: KETAFREE — NRX Pharmaceuticals Inc. — Regulatory Decision
- 2026-07-30: MR-100A-01(Low dose estrogen weekly patch (150 mcg norelgestromin and 17.5 mcg ethinyl estradiol)) — Viatris Inc. — Regulatory Decision
- 2026-07-31: RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3) — Replimune Group Inc. — Regulatory Decision
- 2026-07-31: RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3) — Replimune Group Inc. — Regulatory Decision
- 2026-07-31: QRX003 — Quoin Pharmaceuticals Ltd. — Regulatory Decision
- 2026-07-31: Teverelix - (PRECISION-E2) — Medicus Pharma Ltd. — End of Phase Meeting
FDA Events Calendar
July 2026
Sun
Mon
Tue
Wed
Thu
Fri
Sat
3
4
5
9
16
19
20
21
22
23
24
25
27
28
30
Clinical Read
Regulatory
Meetings & Presentations